Global News Roundup: Q2 2023
Windrose Consulting Group, Global News Roundup: Q2 2023
Life science News from around the world
We are pleased to launch the next edition of our quarterly Windrose Consulting Group: Global News Roundup for Q2 2023
In this edition, we look at many key changes in the Global Life Sciences industry, such as: how the proposed reform of EU pharmaceutical legislation could change the innovation landscape in Europe; France launching a two-year “direct access” scheme experiment to accelerate and improve patient access to innovative medicines; the FDA in the US approving the first two vaccines for respiratory syncytial virus (RSV) for individuals 60 years and older; Mexico, Colombia and Cuba, moving ahead with plans to create a new Latin American and Caribbean Medicines Agency; plus more coverage from around the world.
Our contributing editors for this edition are:
Kristina Funk
James O’Brien
Steven Lin
Itamar Carrillo
Adrian Jung
Joana Lama
Amy Morgan
Windrose Consulting Group, Strategic guidance for Life Sciences.
Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their products, to help meet today’s most critical healthcare needs. We work across a broad range of products and disease areas. Our services that include product commercialization, pricing and market access and value communication. At Windrose, we’re committed to helping companies succeed in bringing innovations to market that enhance people’s lives. We work globally and have three offices, based in Philadelphia (US), London (UK) and Lucerne (Switzerland).